Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 231 to 240 of 1090 total matches.
Prozac Weekly
The Medical Letter on Drugs and Therapeutics • Apr 02, 2001 (Issue 1101)
:423).
INTERACTIONS — Fluoxetine interacts with many other drugs (Medical Letter Handbook
of Adverse ...
The FDA has approved a new formulation of fluoxetine for once-weekly maintenance treatment of depression in patients who have responded to daily fluoxetine (Prozac).
Icosapent Ethyl (Vascepa) for Severe Hypertriglyceridemia
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013 (Issue 1415)
INTERACTIONS — No clinically significant
drug-drug interactions have been reported with icosapent
ethyl ...
Icosapent ethyl (Vascepa [vas EE puh] – Amarin), the
ethyl ester of eicosapentaenoic acid (EPA), has been
approved by the FDA as an adjunct to diet for treatment of
severe hypertriglyceridemia (≥500 mg/dL). Vascepa is
the second omega-3 polyunsaturated fatty acid (PUFA)
product to become available by prescription for this indication;
Lovaza (formerly Omacor), which is a combination
of the ethyl esters of EPA and docosahexaenoic acid
(DHA), was the first. Many omega-3 PUFA-containing
fish oil capsules are sold over the counter as dietary supplements.
Quinupristin/Dalfopristin
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999 (Issue 1066)
and may be severe. Increases in
conjugated bilirubin have occurred frequently.
DRUG INTERACTIONS — Quinupristin ...
Quinupristin and dalfopristin, two streptogramin antibacterials marketed in a 30:70 combination as Synercid, have received accelerated approval from the FDA for intravenous treatment of bacteremia and life-threatening infection....
In Brief: Toxicity of Gadolinium-Based Contrast Agents
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D ...
Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based contrast agents could cause nephrotoxicity and acute renal failure. Some recent reports have suggested, however, that gadolinium-based agents may also be nephrotoxic.1 One patient who developed acute renal failure after use of gadolinium-based contrast had a renal biopsy that showed acute tubular injury.2Moreover, after exposure to gadolinium-based contrast, some patients with severe renal insufficiency,...
Exemestane For Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000 (Issue 1076)
).
DRUG INTERACTIONS — Inducers of CYP3A4, such as rifampin, might decrease serum
concentrations ...
The FDA has approved exemestane, an aromatase inhibitor, for the treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen.
In Brief: New Propellants for Albuterol Metered-Dose Inhalers
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008 (Issue 1298)
Eric J. Epstein, M.D. Albert Einstein College of Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS ...
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future.Three HFA albuterol inhalers and one...
In Brief: Melamine
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008 (Issue 1297)
Einstein College of Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
Belimumab (Benlysta) for Systemic Lupus Erythematosus
The Medical Letter on Drugs and Therapeutics • Jun 13, 2011 (Issue 1366)
during and for 4 months after stopping treatment with
the drug.
DRUG INTERACTIONS — Drug interactions ...
Belimumab (Benlysta – Human Genome Sciences/GlaxoSmithKline) has been approved by the FDA for
treatment of adults with active, autoantibody-positive, systemic lupus erythematosus (SLE). It is the first biologic
agent approved for SLE and the first drug of any kind to be approved for this disease in >50 years.
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
, and liver enzyme elevations were most common.
Drug Interactions: Use with organic anion transporter 1 ...
The FDA has approved Xacduro (Innoviva), a
combination of the beta-lactam antibacterial
sulbactam and the beta-lactamase inhibitor
durlobactam, for IV treatment of adults with hospital-acquired
or ventilator-associated bacterial pneumonia
caused by susceptible isolates of Acinetobacter
baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90 doi:10.58347/tml.2023.1690c | Show Introduction Hide Introduction
Arformoterol (Brovana) for COPD
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
July 2, 2007
DRUG INTERACTIONS — The cardiovascular
effects of beta
2
-agonists can be potentiated ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)